Background
Phase III, open-label RCT (STaMINA, BMT CTN 0702). 758 patients with NDMM in CR or VGPR following a single ASCT (high-dose melphalan 200mg/m²), randomized to 3 consolidation/maintenance strategies. Designed to determine whether tandem ASCT or post-ASCT VRd consolidation improves PFS over direct lenalidomide maintenance, addressing European data suggesting tandem-transplant benefit (EMN02).
Interventions and follow up
Arm A: single ASCT → lenalidomide maintenance 10mg days 1–21 q28d until progression (no consolidation)
Arm B: tandem ASCT (second ASCT 6 months after first, high-dose melphalan 200mg/m²) → lenalidomide maintenance until progression
Arm C: single ASCT → VRd consolidation (bortezomib 1.3mg/m² + lenalidomide 25mg + dexamethasone 20mg ×4 cycles) → lenalidomide maintenance until progression
Primary endpoint: 38-month progression-free survival
Median follow up: 76 months (long-term update)
Arm B: tandem ASCT (second ASCT 6 months after first, high-dose melphalan 200mg/m²) → lenalidomide maintenance until progression
Arm C: single ASCT → VRd consolidation (bortezomib 1.3mg/m² + lenalidomide 25mg + dexamethasone 20mg ×4 cycles) → lenalidomide maintenance until progression
Primary endpoint: 38-month progression-free survival
Median follow up: 76 months (long-term update)
Results
38-month PFS (Arm A, maintenance only): 43.6%
38-month PFS (Arm B, tandem ASCT): 46.5% — HR 0.90, P=.37, NS
38-month PFS (Arm C, VRd consolidation): 42.4% — HR 0.97, P=.83, NS
5-year OS: 71.2% vs 72.8% vs 68.7% — NS
High-risk cytogenetics subgroup (tandem ASCT): trend toward benefit, HR 0.72, P=.17 (exploratory, NS)
38-month PFS (Arm B, tandem ASCT): 46.5% — HR 0.90, P=.37, NS
38-month PFS (Arm C, VRd consolidation): 42.4% — HR 0.97, P=.83, NS
5-year OS: 71.2% vs 72.8% vs 68.7% — NS
High-risk cytogenetics subgroup (tandem ASCT): trend toward benefit, HR 0.72, P=.17 (exploratory, NS)
Adverse events
Transplant/neurologic: tandem ASCT added second-transplant toxicities (mucositis, infections, delay to maintenance); VRd consolidation grade ≥2 neuropathy 28% (bortezomib)
Hematologic: lenalidomide maintenance grade ≥3 neutropenia 36%
Second primary malignancy: numerically highest in Arm C (cumulative bortezomib + lenalidomide exposure)
Hematologic: lenalidomide maintenance grade ≥3 neutropenia 36%
Second primary malignancy: numerically highest in Arm C (cumulative bortezomib + lenalidomide exposure)
Conclusions
Neither tandem ASCT nor VRd consolidation improved PFS or OS vs single ASCT followed directly by lenalidomide maintenance. Single ASCT + lenalidomide maintenance remains the US standard for transplant-eligible NDMM in CR/VGPR after induction.
Key Limitations
Induction regimens were heterogeneous (VRd, VCd, others) without standardization — modern Dara-VRd induction (PERSEUS) may change the role of tandem ASCT. The high-risk cytogenetics subgroup showed a non-significant trend favoring tandem ASCT that may be clinically meaningful and remains debated. The long-term update (Hari 2021, 76 months) confirmed no OS difference. European data (EMN02 tandem cohort) suggested tandem benefit in high-risk cytogenetics — discordant with STaMINA.
Clinical Context
STaMINA established single ASCT + lenalidomide maintenance as the US standard of care for transplant-eligible NDMM, diverging from European practice where tandem ASCT is more widely used (particularly in high-risk cytogenetics). The discordance with EMN02 reflects differences in induction regimens, patient selection, and consolidation. With Dara-VRd induction (PERSEUS), deeper pre-ASCT responses may further reduce the incremental benefit of tandem ASCT; MRD-guided approaches may individualize the decision.